PAS
CRVS icon

PKS Advisory Services’s Corvus Pharmaceuticals CRVS Stock Holding History

PKS Advisory Services’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,500
Closed -$77.4K – 258
2025
Q3 		$77.4K Hold
10,500
– – 0.02% 241
2025
Q2 		$42K Hold
10,500
– – 0.01% 259
2025
Q1 		$33.4K Hold
10,500
– – 0.01% 241
2024
Q4 		$56.2K Buy
+10,500
New +$78.4K 0.01% 243

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PKS Advisory Services's CRVS Position: Q4 2025 in Review

PKS Advisory Services sold out of Corvus Pharmaceuticals (CRVS) in Q4 2025, closing a stake of 10,500 shares — an estimated $77.4K sold.

PKS Advisory Services first reported a position in CRVS in Q4 2024 and held it in 4 quarters. The position peaked at $77.4K in Q3 2025. 124 funds tracked by Wall St. Rank hold CRVS as of Q4 2025.

  • PKS Advisory Services reported no remaining Corvus Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • PKS Advisory Services sold 10,500 Corvus Pharmaceuticals shares in Q4 2025, an estimated $77.4K.
  • PKS Advisory Services first reported a position in Corvus Pharmaceuticals in Q4 2024 and held it in 4 quarters.
  • PKS Advisory Services's Corvus Pharmaceuticals position peaked at $77.4K in Q3 2025.
  • 124 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q4 2025.

Based on PKS Advisory Services's 13F filing for Q4 2025, filed 2 Feb 2026.